Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis

Abstract

Among patients with osteoporosis who were at high risk for fracture, bone mineral density increased more in patients receiving teriparatide than in those receiving alendronate. (ClinicalTrials.gov number, NCT00051558 [ClinicalTrials.gov].).